The effect of moringa oleifera leaf extract on the inflammation status of breast cancer patients receiving hormonal therapy

Not Applicable

Completed

• Conditions: Moringa Oleifera leaf extract reduces inflammation status of breast cancer patients with estrogen receptor (+) and estrogen receptor (+) receiving Aromatase Inhibitor Therapy; Cancer

• Registration Number: ISRCTN11510869
• Lead Sponsor: Diponegoro University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-09-28
• Study Start: 2022-12-01
• Last Update Posted: 2 August 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 78

Inclusion Criteria

1. Breast cancer patient
2. Post menopause
3. Imunohistokimia Estrogen receptor (+), Progesteron receptor (+)
4. Received aromatase inhibitor
5. Patient with Aromatase Inhibitor-Associated Musculoskeletal Syndrome

Exclusion Criteria

1. Emergency condition that needs operation
2. Visceral metastasis
3. History of previous degenerative joint and soft tissue disease (osteoarthritis/rheumatoid arthritis).
4. History of fracture during the last 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Inflammation status is measured using data on the levels of ESR, CRP, CPK, and ANA. Data is gathered pre-treatment and after treatment (30 days)

Secondary Outcome Measures

Name	Time	Method
<br> Measured using blood test:<br> 1. Erythrocyte Sedimentation rate (ESR) measured at pre-treatment and after treatment (30 days)<br> 2. C-Reactive Protein (CRP) measured at pre-treatment and after treatment (30 days)<br> 3. Anti-Nuclear Antibody (ANA) measured at pre-treatment and after treatment (30 days)<br> 4. Creatine Phosphokinase (CPK) measured at pre-treatment and after treatment (30 days)<br>